Skip to content

Clinical and Biological Database in Colon Cancer and Colic Tumors

Prospective, Multicenter, Clinical and Biological Database Set-up in Colon Cancer and Colic Tumors

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03976960
Acronym
BCBCOLON
Enrollment
600
Registered
2019-06-06
Start date
2018-09-19
Completion date
2030-12-31
Last updated
2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Colon

Keywords

cancer, colon, tumor, colic

Brief summary

Developement of a clinical and biological database in colon cancer and colic tumors in order to better understand tumor invasion and metastatic scattering processes. The investigators hope that a better understanding of tumoral invasion process will lead to the discovery of new biomarkers and new drugs.

Detailed description

As the second leading cause of cancer-related death in France, colorectal cancer is a major public health problem. Each year, 37 000 cases are newly diagnosed in France and 17 000 patients die of the disease. Colorectal cancer is due to molecular and genetic damages involved in all tumorigenesis steps, transition from healthy tissue to adenoma and finally to invasive carcinoma stage. The investigators hope that a to better understand tumor invasion and metastatic scattering processes will allow therapeutic innovation and the emergence of new biomarkers. However, the study of early tumorigenesis phases as well as advanced stages of the disease is currently limited due to a lack of tissue samples. In this context, the Montpellier Cancer Institute (ICM) decided to initiate a biological collection dedicated to the tissular and blood samples of patients with colorectal cancer.

Interventions

OTHERBiological collection

The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.

Sponsors

Institut du Cancer de Montpellier - Val d'Aurelle
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient undergoing colon cancer surgery (stage I, II, III and IV) 2. Patient operated for liver or lung or peritoneal carcinomatosis metastases originating from colon cancer 3. Patient operated for pre-neoplastic lesion (adenomatous polyp /villous adenoma polyp), 4. Patient with familial polyposis eligible for colectomy 5. Age \> 18 years 6. Signed informed consent

Exclusion criteria

1. Patient not affiliated to Social Protection system 2. Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons 3. Patient under guardianship 4. Minor patient

Design outcomes

Primary

MeasureTime frame
Number of clinical risk factors for colorectal cancerUntil the study completion : 6 years
Number of biological risk factors for colorectal cancerUntil the study completion : 6 years

Countries

France

Contacts

Primary ContactAurore MOUSSION
DRCI-icm105@icm.unicancer.fr4 67 61 31 02

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026